Update shared on15 Aug 2025
Rani Therapeutics Holdings’ lower future P/E and declining net profit margin highlight reduced growth expectations, which is reflected in the consensus price target holding steady at $7.75.
What's in the News
- Filed a $2.99 million follow-on equity offering via registered direct offering, including Class A common stock and pre-funded warrants at significant discount.
- Added to several Russell indexes, including Russell 3000E, Russell Microcap, and their Growth benchmarks.
- Received Nasdaq notice for non-compliance with minimum $1 bid price, with a 180-day cure period and potential for further extension or delisting risk.
- Entered a research agreement with Chugai Pharmaceutical for two molecules, with RaniPill® delivery showing comparable bioavailability to subcutaneous administration.
Valuation Changes
Summary of Valuation Changes for Rani Therapeutics Holdings
- The Consensus Analyst Price Target remained effectively unchanged, at $7.75.
- The Future P/E for Rani Therapeutics Holdings has significantly fallen from 84.34x to 59.06x.
- The Net Profit Margin for Rani Therapeutics Holdings has fallen from 23.22% to 21.85%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.